Aileron Therapeutics, Inc. announced that Joseph A. Yanchik III has resigned as president and chief executive officer of the company and as a member of its board of directors. Biopharma industry veteran John P. Longenecker, Ph.D. has been named interim chief executive officer. Dr. Longenecker brings 30 years of executive management experience to Aileron.

John leadership experience extends from operations and R&D to commercial launch, venture funding, secondary public offerings and corporate partnering.